Mankind Pharma reports 19% revenue growth, acquires BSV
Mankind Pharma reported revenue of ₹12,207.44 crores for financial year 2024-25, marking 19% year-on-year growth, with net profit of ₹2,006.59 crores.
The company acquired a 100% stake in Bharat Serums and Vaccines Limited for ₹13,768 crore, expanding its presence in complex super-specialty segments.
Mankind Pharma also entered licensing agreements with AstraZeneca, Novartis, and Innovent Biologics to strengthen its product portfolio. The company increased R&D allocation to 2.5%-3.0% of revenue for FY2026.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Mankind Pharma publishes news
Free account required • Unsubscribe anytime